Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MC4R | P32245 | 3/20 | 0.37 |
| ▸ | ACP3 | P15309 | 1/20 | 0.36 |
| ▸ | METAP2 | P50579 | 1/20 | 0.36 |
| ▸ | METAP1 | P53582 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | XBP1 | P17861 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7898964 | 1.00 | KEAP1 (0.44) | KEAP1MEN1KMT2APLA2G1BATM | |
| SCHEMBL7896540 | 0.97 | KEAP1 (0.44) | KEAP1MEN1KMT2APLA2G1BATM | |
| SCHEMBL7896612 | 0.95 | KEAP1 (0.45) | KEAP1MEN1KMT2APLA2G1BATM | |
| Hydrochloric Acid SCHEMBL17871924 | 0.88 | KEAP1 (0.39) | KEAP1MEN1KMT2APLA2G1BATM | |
| SCHEMBL7898810 | 0.82 | MEN1 (0.43) | KEAP1MEN1KMT2APLA2G1BATM | |
| SCHEMBL7896616 | 0.81 | GAA (0.42) | KEAP1MEN1KMT2AMAPK1NPC1 | |
| SCHEMBL7895952 | 0.80 | MEN1 (0.45) | KEAP1MEN1KMT2AMAPK1GAA | |
| SCHEMBL7888872 | 0.78 | KEAP1 (0.49) | KEAP1MAPK1NPC1GAAMC4R | |
| SCHEMBL1964089 | 0.77 | MC4R (0.54) | KEAP1MAPK1NPC1GAAMC4R | |
| SCHEMBL442668 | 0.77 | MC4R (0.54) | KEAP1MAPK1NPC1GAAMC4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3237396-B1 | HETEROCYCLIC DERIVATIVES AS RORGAMMA MODULATORS | GENFIT (FR) | 2019-07-03 | — | — | EP | disclosed |
| US-9902725-B2 | Heterocyclic derivatives as RORgamma modulators | GENFIT (FR) | 2018-02-27 | — | — | US | disclosed |
| US-20170349582-A1 | HETEROCYCLIC DERIVATIVES AS RORGAMMA MODULATORS | GENFIT (FR) | 2017-12-07 | — | — | US | disclosed |
| EP-3237396-A1 | HETEROCYCLIC DERIVATIVES AS RORGAMMA MODULATORS | Genfit (FR) | 2017-11-01 | — | — | EP | disclosed |
| WO-2016102633-A1 | HETEROCYCLIC DERIVATIVES AS RORGAMMA MODULATORS | GENFIT (FR) | 2016-06-30 | — | — | WO | disclosed |
| US-20060079696-A1 | Substituted compounds derived from N-(benzyl)phenylacetamide, preparation and uses | GENFIT (FR) | 2006-04-13 | — | — | US | disclosed |
| WO-2006035157-A2 | SUBSTITUTED N-(BENZYL)PHENYLACETAMIDE DERIVATIVE COMPOUNDS, PREPARATION METHOD THEREOF AND USES OF SAME AS PPAR LIGANDS IN THE TREATMENT OF LIPID AND/OR GLUCIDIC DISORDERS | GENFIT (FR) | 2006-04-06 | — | — | WO | disclosed |
| US-RE37035-E1 | HYPOGLYCEMIC AGENTS | BOEHRINGER INGELHEIM KG (DE) | 2001-01-30 | — | — | US | disclosed |
| US-6143769-A | ENANTIOMORPH | KARL THOMAE GMBH (DE) | 2000-11-07 | — | — | US | disclosed |
| US-5312924-A | Compounds for lowering blood sugar and effecting metabolism | DR. KARL THOMAE GMBH (DE) | 1994-05-17 | — | — | US | disclosed |
| US-5216167-A | Hypoglycemic agents | DR. KARL THOMAE GMBH (DE) | 1993-06-01 | — | — | US | disclosed |
| EP-0208200-B1 | PHENYLACETIC-ACID DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESSES FOR THEIR PRODUCTION | Dr. Karl Thomae GmbH (DE) | 1990-04-25 | — | — | EP | disclosed |
| EP-0208200-A1 | Phenylacetic-acid derivatives, pharmaceutical compositions containing them and processes for their production | Dr. Karl Thomae GmbH (DE) | 1987-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170349582-A1 | HETEROCYCLIC DERIVATIVES AS RORGAMMA MODULATORS | RORC, RORB, RORA | KEAP1 1098/4885MEN1 3408/4885KMT2A 2603/4885 |
| US-20060079696-A1 | Substituted compounds derived from N-(benzyl)phenylacetamide, preparation and uses | AADAC, NAT1, PARN | KEAP1 714/4885MEN1 3321/4885KMT2A 954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.